Janssen has built a legacy of innovation in the treatment of prostate cancer, the second most common cancer in men worldwide. We have developed a novel agent for patients with metastatic castration-resistant prostate cancer (mCRPC) and, more recently, for patients with high-risk castration-sensitive prostate cancer. We are driven by the fact that, for patients with advanced disease and for those at high-risk of developing castration-resistant prostate cancer, this is a deadly illness. Patients with newly identified metastatic disease, either at first diagnosis or following prior local therapy, have a poorer prognosis. For patients with non-metastatic castration-resistant prostate cancer, the median overall survival is less than 5 years, and for patients with metastatic castration-resistant prostate cancer, median overall survival is less than 3 years in chemotherapy naïve men.
We have increased our understanding of the biology underpinning various types of prostate cancer, progressing research from innovations in late-stage treatments to intervening earlier in the disease before patients become castration-resistant. Our work has resulted in a first-in-class therapy for patients with non-metastatic castration-resistant prostate cancer. Our goal is to one day stop prostate cancer from spreading by focusing on high-risk localized disease.
We are leveraging novel endpoints to bring new transformational therapies to patients and are evaluating the benefits of combining therapies in our portfolio, as well as bringing new compounds into clinical development with the goal of extending life and helping patients enjoy the highest possible quality of life.